把鏡像異構物分開，31a (即 Zanubrutinib), 32a, 33a 在藥理活性上表現優異，團隊以藥物讓酵素去活化的速率（k inact）/ 藥物抑制速率常數（K I) 評估藥物與蛋白質形成共價鍵的效果，結果顯示 31a ≈ Ibrutinib > 31b。

2024年3月12日 · Zanubrutinib is a targeted treatment that may be used to treat adults with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and Waldenström's macroglobulinemia (WM). It may also be used to treat people who meet certain criteria with Mantl

Zanubrutinib must be administered orally before obinutuzumab infusion. The recommended dose is obinutuzumab 1,000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and on Day 1 of every 28-day cycle from Cycles 2 to 6. At the discretion of …

BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen. This indication is...

2022年2月17日 · Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor evaluated in multiple B-cell malignancy studies. We constructed a pooled safety analysis to better understand zanubrutinib-associated treatment-emergent adverse events (TEAEs) and identify treatment-limiting toxicities. Data were pooled from 6 studies (N = 779).

2023年11月15日 · The primary analysis of MAGNOLIA, an open-label, single-arm, multicenter, phase 2 study, demonstrated that the next-generation Bruton tyrosine kinase (BTK) inhibitor zanubrutinib provided a high overall response rate (ORR) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL), with a favorable safety/tolerability profile.

2023年9月11日 · In this article, we review the development of zanubrutinib, a next-generation BTK inhibitor, from molecular design to patient-related outcomes. We start this journey by providing insights into the discovery of BTK and the physiologic, genetic, and molecular characterization of patients lacking this kinase, together with the brief treatment ...

2019年8月5日 · Compound BGB-3111 (31a, Zanubrutinib) demonstrates (i) potent activity against BTK and excellent selectivity over other TEC, EGFR and Src family kinases, (ii) desirable ADME, excellent in vivo pharmacodynamic in mice and efficacy in OCI-LY10 xenograft models.

Zanubrutinib may cause temporary changes in your blood counts. Your doctor will be following these changes carefully by ordering regular blood tests. Adjustment of your treatment may be needed in certain circumstances.

Zanubrutinib is an orally administered, highly-specific, small molecule inhibitor of Bruton’s tyrosine kinase (BTK). BTK is an integral part of the B-cell antigen receptor (BCR) pathway, which is associated with the pathogenesis of several B-cell malignancies. Zanubrutinib forms a covalent bond with a cysteine residue in the BTK active site,